1. In Vivo
  2. >>Deal-Making

Financing Quarterly Statistics, Q3 2022

A Look At Financing Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, July-September 2022

 
• By Deanna Kamienski and Maureen Riordan

During Q3, biopharmas brought in an aggregate $18.1bn in financing and device company fundraising totaled $5.1bn; while in vitro diagnostic firms and research tools players raised $771m.

Qstats Image 1
• Source: Alamy

Biopharma financings during the third quarter of 2022 totaled $18.1bn from 236 deals. The largest was a $1.39bn royalty sale by Theravance Biopharma to Royalty Pharma, which acquired an 85% royalty interest in Theravance Biopharma Inc.’s asthma/COPD drug Trelegy Ellipta (fluticasone furoate, umeclidinium, vilanterol) for $1.1bn in cash up front and up to $250m in additional payments contingent on the achievement of certain sales milestones anticipated to occur between 2023-2026.

The Trelegy royalties are payable to Theravance from GlaxoSmithKline Pharmaceuticals Ltd. under an alliance initially signed in 2004....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.